Vivos Therapeutics expands at-the-market equity offering under existing agreement

Vivos Therapeutics, Inc.

Filed prospectus supplement to increase aggregate offering price of common stock under ATM agreement with H.C. Wainwright & Co. (dated Feb 14, 2025).
No specific increase amount or prior cap disclosed in the 8-K filing.
Legal opinion on share issuance attached as Exhibit 5.1; no other material changes reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.